Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
German biotech BioNTech, which shot into the limelight with the development of the most successful COVID-19 vaccine, Comirnaty, has reported financial results for the three months ended March 31, 2024. 7 May 2024
Biotechnology
The prestigious New England Journal of Medicine (NEJM) has published interim results from the Phase III trial of Japanese drug major Takeda Pharma’s Adzynma (apadamtase alfa/cinaxadamtase alfa; code name TAK-755) in patients with congenital thrombotic thrombocytopenic purpura (cTTP). 5 May 2024
Pharmaceutical
Sentynl, the USA-based wholly-owned subsidiary of Indian generics major Zydus Lifesciences, has announced the closing of the sale of Eiger BioPharmaceuticals’ Zokinvy (lonafarnib) program to Sentynl. 4 May 2024
Biotechnology
CSL Seqirus, a business of Australia's CSL, has announced positive efficacy data from a real-world evidence (RWE) study of influenza vaccines. 3 May 2024
Biotechnology
Shares in US mRNA specialist Moderna were 7% higher during Thursday morning’s trading. 2 May 2024
Biotechnology
mRNA specialist Moderna has opted to end its collaboration with fellow US biotech Metagenomi on primary hyperoxaluria type 1 (PH1). 2 May 2024
Biotechnology
Sanofi’s Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalizations by 82% in infants under six months of age, compared to babies who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. 2 May 2024
Pharmaceutical
At $14.9 billion, New York-based Pfizer has beaten estimates for first quarter revenues and raised its profit outlook accordingly. 1 May 2024
Biotechnology
UK clinical-stage biotech Barinthus Biotherapeutics, formerly Vaccitech, today announced the appointment of Dr Leon Hooftman as chief medical officer (CMO). 1 May 2024
Pharmaceutical
US pharma giant Merck & Co has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), at the European Society of Clinical Microbiology and Infectious Diseases event in Barcelona, Spain. 30 April 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze